Nature Biotechnology Podcast show

Nature Biotechnology Podcast

Summary: Nature Biotechnology podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.

Join Now to Subscribe to this Podcast

Podcasts:

 First Rounder: Stan Crooke | File Type: audio/mpeg | Duration: 1:04:41

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.

 First Rounder: Stanley Crooke | File Type: audio/mpeg | Duration: 1:04:40

Stan Crooke discusses his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.

 First Rounder: Rachel King | File Type: audio/mpeg | Duration: 58:09

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.

 First Rounder: Rachel King | File Type: audio/mpeg | Duration: 00:58:09

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.

 First Rounder: Colin Goddard | File Type: audio/mpeg | Duration: 00:58:09

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.

 First Rounder: Colin Goddard | File Type: audio/mpeg | Duration: 58:09

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.

 First Rounder: Kari Stefansson | File Type: audio/mpeg | Duration: 00:55:28

Kari Stefansson's conversation with Nature Biotechnology covers the founding of deCODE, his love for literature (and his favorite poet), plus his encounter with the tortured chess grandmaster Bobby Fischer.

 First Rounder: Kari Stefansson | File Type: audio/mpeg | Duration: 55:27

Kari Stefansson talks about the founding of deCODE, his love for literature (and his favorite poet), plus his encounter with the tortured chess grandmaster Bobby Fischer.

 First Rounder: Carl Feldbaum | File Type: audio/mpeg | Duration: 1:07:32

Carl Feldbaum was the founding president of the Biotechnology Industry Organization (BIO), and he is the current chairman of the Life Sciences Foundation. His podcast conversation with Nature Biotechnology touches on his assistance in prosecuting Watergate, his visit to Saddam Hussein's palace and how he built BIO from the ground up.

 First Rounder: Carl Feldbaum | File Type: audio/mpeg | Duration: 1:07:32

Carl Feldbaum was the founding president of the Biotechnology Industry Organization (BIO), and he is the current chairman of the Life Sciences Foundation. His podcast conversation with Nature Biotechnology touches on his assistance in prosecuting Watergate, his visit to Saddam Hussein's palace and how he built BIO from the ground up.

 First Rounder: Daphne Zohar | File Type: audio/mpeg | Duration: 00:48:38

Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her podcast conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital. (Updated February 6, 2015).

 First Rounder: Daphne Zohar | File Type: audio/mpeg | Duration: 48:37

Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her podcast conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital.

 First Rounder: Mary Tanner | File Type: audio/mpeg | Duration: 56:34

Mary Tanner details the Amgen-Immunex buyout, defines 'wildcatting' and suggests the years in which children most need a parent around the house.

 First Rounder: Mary Tanner | File Type: audio/mpeg | Duration: 00:56:34

Mary Tanner details the Amgen-Immunex buyout, defines 'wildcatting' and suggests the years in which children most need a parent around the house.

 Nature Biotechnology focus issue podcast | File Type: audio/mpeg | Duration: 39:54

Anthony Davies discusses the past, present and future of stem cell therapies.

Comments

Login or signup comment.